-
公开(公告)号:US20150037394A1
公开(公告)日:2015-02-05
申请号:US14128457
申请日:2012-06-22
CPC分类号: A61K47/08 , A61F7/03 , A61F2007/0226 , A61F2007/0261 , A61F2007/0276 , A61F2007/0292 , A61K9/0004 , A61K9/0014 , A61K9/06 , A61K9/08 , A61K9/12 , A61K9/703 , A61K31/167 , A61K31/519 , A61K47/10 , A61K47/12
摘要: Mixtures of C1-12 compounds comprising at least one -Alk-O— group with thermogenic formulations, such as those comprising supercooled solutions of salts, are capable of substantial enhancement of transdermal drug delivery.
摘要翻译: 包含至少一个-Alk-O-基团的生成制剂的C1-12化合物的混合物,例如包含过冷的盐溶液的那些,能够显着增强透皮药物递送。
-
公开(公告)号:US08349297B2
公开(公告)日:2013-01-08
申请号:US12067004
申请日:2006-09-14
IPC分类号: A61K9/12
摘要: Saturated, monophasic solutions of drug in a solvent and propellant mixture, together with a film-forming agent, exhibit transdermal diffusion fluxes greater than those predicted by Fick's law when applied topically.
摘要翻译: 药物在溶剂和推进剂混合物中的饱和单相溶液与成膜剂一起显示出比局部应用时通过菲克定律预测的透皮扩散通量更大的透皮扩散通量。
-
公开(公告)号:US20090191271A1
公开(公告)日:2009-07-30
申请号:US12067004
申请日:2006-09-14
摘要: Saturated, monophasic solutions of drug in a solvent and propellant mixture, together with a film-forming agent, exhibit transdermal diffusion fluxes greater than those predicted by Fick's law when applied topically.
摘要翻译: 药物在溶剂和推进剂混合物中的饱和单相溶液与成膜剂一起显示出比局部应用时通过菲克定律预测的透皮扩散通量更大的透皮扩散通量。
-
公开(公告)号:US20080207537A1
公开(公告)日:2008-08-28
申请号:US11916514
申请日:2006-06-06
IPC分类号: A61K31/7048 , A61K47/22 , A61K47/20 , A61K47/18 , A61K47/14 , A61K47/12 , A61K47/02 , A61K31/343 , A61K31/513 , A61P31/10 , A61K31/436 , A61K31/519 , A61K31/506 , A61K31/5375 , A61K31/4174 , A61K31/496 , A61K31/4196 , A61K31/4164 , A61K31/135
摘要: Application of a reducing agent followed by an oxidising agent to a nail substantially increases the permeability thereof, thereby enabling the passage of drugs across the nail.
摘要翻译: 将还原剂和氧化剂施用于指甲后,可大大提高其渗透性,从而使药物能穿过指甲。
-
公开(公告)号:US20120295971A1
公开(公告)日:2012-11-22
申请号:US13563720
申请日:2012-07-31
CPC分类号: A61K31/22 , A61K9/0014 , A61K9/06 , A61K31/215 , A61K36/47 , A61K47/10 , A61K47/12 , A61K47/32 , A61K47/38
摘要: Ingenol angelate is a potent anticancer agent, and can be stabilised by dissolving it in an aprotic solvent in the presence of an acidic buffer.
-
公开(公告)号:US08278292B2
公开(公告)日:2012-10-02
申请号:US12097258
申请日:2006-12-18
CPC分类号: A61K31/22 , A61K9/0014 , A61K9/06 , A61K31/215 , A61K36/47 , A61K47/10 , A61K47/12 , A61K47/32 , A61K47/38
摘要: Ingenol angelate is a potent anticancer agent, and can be stabilized by dissolving it in an aprotic solvent in the presence of an acidic buffer.
摘要翻译: 当归酸根是一种有效的抗癌剂,可以通过在酸性缓冲液存在下将其溶于非质子溶剂而稳定化。
-
公开(公告)号:US20090292017A1
公开(公告)日:2009-11-26
申请号:US12097258
申请日:2006-12-18
CPC分类号: A61K31/22 , A61K9/0014 , A61K9/06 , A61K31/215 , A61K36/47 , A61K47/10 , A61K47/12 , A61K47/32 , A61K47/38
摘要: Ingenol angelate is a potent anticancer agent, and can be stabilised by dissolving it in an aprotic solvent in the presence of an acidic buffer.
摘要翻译: 当归酸根是一种有效的抗癌剂,可以通过在酸性缓冲液存在下将其溶于非质子溶剂而稳定化。
-
公开(公告)号:US20120295970A1
公开(公告)日:2012-11-22
申请号:US13563716
申请日:2012-07-31
CPC分类号: A61K31/22 , A61K9/0014 , A61K9/06 , A61K31/215 , A61K36/47 , A61K47/10 , A61K47/12 , A61K47/32 , A61K47/38
摘要: Ingenol angelate is a potent anticancer agent, and can be stabilised by dissolving it in an aprotic solvent in the presence of an acidic buffer.
-
9.USE OF PYRROLOQUINOLINE COMPOUNDS TO KILL CLINICALLY LATENT MICROORGANISMS 审中-公开
标题翻译: 吡咯啉化合物杀死临床微生物的用途公开(公告)号:US20120231995A1
公开(公告)日:2012-09-13
申请号:US13473707
申请日:2012-05-17
申请人: Petra Helga Beck , Marc Barry Brown , David Edward Clark , Anthony Coates , Hazel Joan Dyke , Yanmin Hu , Derek John Londesbrough , Keith Mills , Thomas David Pallin , Gary Patrick Reid , Gerlinda Stoddart
发明人: Petra Helga Beck , Marc Barry Brown , David Edward Clark , Anthony Coates , Hazel Joan Dyke , Yanmin Hu , Derek John Londesbrough , Keith Mills , Thomas David Pallin , Gary Patrick Reid , Gerlinda Stoddart
IPC分类号: A61K31/4745 , A01N43/90 , A61K31/5377 , A61K31/497 , A61K31/496 , A61K31/43 , A61K31/7052 , A61K38/12 , A61K31/5383 , A61P31/00 , A01P1/00 , A61P31/06 , A61P31/04 , A61P17/10 , A61P1/04 , A61P11/08 , A61P17/02 , A61P29/00 , A61P1/02 , A61P11/00 , A61P27/02 , A61P15/02 , A61P1/00 , A61P15/00 , A61P31/08 , A61P1/16 , A61P15/14 , A61P25/00 , A61P13/00 , A61P1/18 , A61P13/08 , A61P17/00 , A61P31/10 , A61P33/02 , C07D471/04
CPC分类号: A61K31/4709 , A01N43/90 , A61K31/43 , A61K31/4439 , A61K31/4706 , A61K31/4725 , A61K31/4745 , A61K31/496 , A61K31/497 , A61K31/546 , A61K31/7052 , A61L2/0088 , C07D471/04 , Y02A50/401 , Y02A50/404 , Y02A50/406 , Y02A50/411 , Y02A50/469 , Y02A50/473 , Y02A50/475 , Y02A50/478 , Y02A50/479 , Y02A50/481 , Y02A50/483
摘要: There is provided the use of compounds of formula I wherein R1, R2, R3 and X have meanings given in the description, for the preparation of a medicament for killing clinically latent microorganisms. There is also provided the use of compounds of formula I for treating microbial infections, as well as certain compounds of formula I per se.
摘要翻译: 提供式I化合物的用途,其中R1,R2,R3和X具有描述中给出的含义,用于制备用于杀死临床潜在微生物的药物。 还提供了式I化合物用于治疗微生物感染的用途,以及式I本身的某些化合物。
-
10.Use of pyrroloquinoline compounds to kill clinically latent microorganisms 有权
标题翻译: 使用吡咯喹啉化合物杀死临床潜在的微生物公开(公告)号:US08207187B2
公开(公告)日:2012-06-26
申请号:US12092947
申请日:2006-11-08
申请人: Petra Helga Beck , Marc Barry Brown , David Edward Clark , Anthony Coates , Hazel Joan Dyke , Yanmin Hu , Derek John Londesbrough , Keith Mills , Thomas David Pallin , Gary Patrick Reid , Gerlinda Stoddart
发明人: Petra Helga Beck , Marc Barry Brown , David Edward Clark , Anthony Coates , Hazel Joan Dyke , Yanmin Hu , Derek John Londesbrough , Keith Mills , Thomas David Pallin , Gary Patrick Reid , Gerlinda Stoddart
IPC分类号: A61K31/4745 , A61P31/04 , C07D471/14 , C07D471/04
CPC分类号: A61K31/4709 , A01N43/90 , A61K31/43 , A61K31/4439 , A61K31/4706 , A61K31/4725 , A61K31/4745 , A61K31/496 , A61K31/497 , A61K31/546 , A61K31/7052 , A61L2/0088 , C07D471/04 , Y02A50/401 , Y02A50/404 , Y02A50/406 , Y02A50/411 , Y02A50/469 , Y02A50/473 , Y02A50/475 , Y02A50/478 , Y02A50/479 , Y02A50/481 , Y02A50/483
摘要: There is provided the use of compounds of formula I wherein R1, R2, R3 and X have meanings given in the description, for the preparation of a medicament for killing clinically latent microorganisms. There is also provided the use of compounds of formula I for treating microbial infections, as well as certain compounds of formula I per se.
摘要翻译: 提供式I化合物的用途,其中R1,R2,R3和X具有描述中给出的含义,用于制备用于杀死临床潜在微生物的药物。 还提供了式I化合物用于治疗微生物感染的用途,以及式I本身的某些化合物。
-
-
-
-
-
-
-
-
-